Genetic testing can confirm a muscular dystrophy (MD) diagnosis when symptoms and other tests already suggest MD. It also identifies specific gene mutations that can guide targeted treatment. Genetic ...
On Tuesday, Dyne Therapeutics Inc. (NASDAQ:DYN) announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 ...
On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping ...
Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...
DMD is the result of mutations in the dystrophin gene located on the X chromosome. These mutations lead to the absence or dysfunction of the dystrophin protein, which is essential for muscle stability ...
Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...
As individuals age, maintaining muscular health becomes increasingly crucial, where the loss of muscle mass and strength is linked to a higher risk of falls and reduced physical activity. Now, ...
Spinal muscular atrophy (SMA) type 1 is the most common and most severe form of SMA. Symptoms typically begin in the first 6 months of life. Life expectancy is less than 2 years without treatment, but ...
A serving of quality protein provides the amino acids that muscles need and supports muscle recovery. Clean protein also helps keep a person’s caloric intake manageable without added sugars, fillers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results